SLC2A1 and neoplasm: Treatment with 32-134D also inhibited hypoxia-induced expression of SLC2A1, LDHA, ENTPD1, and CA9 mRNA, which play roles in both tumor metabolism and immune evasion (P < 0.05; Figure 3B and Supplemental Table 4).